Meike L Schipper1,2, Christoph G U Riese3, Stephan Seitz3, Alexander Weber3, Martin Béhé3, Tino Schurrat3, Nils Schramm4, Boris Keil5, Heiko Alfke5, Thomas M Behr3. 1. Department of Nuclear Medicine, Philipps University Marburg, Marburg, Germany. mshipper@stanford.edu. 2. Molecular Imaging Program at Stanford (MIPS) and Department of Radiology, Stanford University, E 150 Clark Center, 318 Campus Drive, Stanford, CA, 94305-5427, USA. mshipper@stanford.edu. 3. Department of Nuclear Medicine, Philipps University Marburg, Marburg, Germany. 4. Department of Electronics, Forschungszentrum Jülich, Jülich, Germany. 5. Department of Radiology, Philipps University Marburg, Marburg, Germany.
Abstract
PURPOSE: There is growing interest in the human sodium/iodide symporter (NIS) gene both as a molecular imaging reporter gene and as a therapeutic gene. Here, we show the feasibility of radioisotope therapy of neuroendocrine tumors. As a separate application of NIS gene transfer, we image NIS-expressing tumors with pinhole SPECT in living subjects. METHODS: Biodistribution studies and in vivo therapy experiments were performed in nude mice carrying stably NIS-expressing neuroendocrine tumor xenografts following i.v. injection of (131)I and (99m)Tc pertechnetate. To show the usefulness of NIS as an imaging reporter gene, (99m)Tc pertechnetate uptake was imaged in vivo using a clinical gamma camera in combination with a custom-made single pinhole collimator, followed by SPECT/small animal MRI data coregistration. RESULTS: NIS-expressing neuroendocrine tumors strongly accumulated (131)I and (99m)Tc pertechnetate, as did thyroid, stomach, and salivary gland. The volume of NIS-expressing neuroendocrine tumors decreased significantly after therapeutic administration of (131)I or (99m)Tc pertechnetate, whereas control tumors continued to grow. NIS-mediated uptake of (99m)Tc pertechnetate could be imaged in vivo at high resolution with a clinical gamma camera equipped with a custom-made single pinhole collimator. High-resolution functional and morphologic information could be combined in a single three-dimensional data set by coregistration of SPECT and small animal MRI data. Lastly, we demonstrated a therapeutic effect of (99m)Tc pertechnetate on NIS-expressing neuroendocrine tumors in cell culture and, for the first time, in vivo, thought to be due to emitted Auger and conversion electrons. CONCLUSIONS: NIS-expressing neuroendocrine tumors efficiently concentrate radioisotopes, allowing for in vivo high-resolution small animal SPECT imaging as well as rendering possible successful radioisotope therapy of neuroendocrine tumors.
PURPOSE: There is growing interest in the humansodium/iodide symporter (NIS) gene both as a molecular imaging reporter gene and as a therapeutic gene. Here, we show the feasibility of radioisotope therapy of neuroendocrine tumors. As a separate application of NIS gene transfer, we image NIS-expressing tumors with pinhole SPECT in living subjects. METHODS: Biodistribution studies and in vivo therapy experiments were performed in nude mice carrying stably NIS-expressing neuroendocrine tumor xenografts following i.v. injection of (131)I and (99m)Tc pertechnetate. To show the usefulness of NIS as an imaging reporter gene, (99m)Tc pertechnetate uptake was imaged in vivo using a clinical gamma camera in combination with a custom-made single pinhole collimator, followed by SPECT/small animal MRI data coregistration. RESULTS:NIS-expressing neuroendocrine tumors strongly accumulated (131)I and (99m)Tc pertechnetate, as did thyroid, stomach, and salivary gland. The volume of NIS-expressing neuroendocrine tumors decreased significantly after therapeutic administration of (131)I or (99m)Tc pertechnetate, whereas control tumors continued to grow. NIS-mediated uptake of (99m)Tc pertechnetate could be imaged in vivo at high resolution with a clinical gamma camera equipped with a custom-made single pinhole collimator. High-resolution functional and morphologic information could be combined in a single three-dimensional data set by coregistration of SPECT and small animal MRI data. Lastly, we demonstrated a therapeutic effect of (99m)Tc pertechnetate on NIS-expressing neuroendocrine tumors in cell culture and, for the first time, in vivo, thought to be due to emitted Auger and conversion electrons. CONCLUSIONS:NIS-expressing neuroendocrine tumors efficiently concentrate radioisotopes, allowing for in vivo high-resolution small animal SPECT imaging as well as rendering possible successful radioisotope therapy of neuroendocrine tumors.
Authors: U Haberkorn; M Henze; A Altmann; S Jiang; I Morr; M Mahmut; P Peschke; W Kübler; J Debus; M Eisenhut Journal: J Nucl Med Date: 2001-02 Impact factor: 10.057
Authors: A Boland; M Ricard; P Opolon; J M Bidart; P Yeh; S Filetti; M Schlumberger; M Perricaudet Journal: Cancer Res Date: 2000-07-01 Impact factor: 12.701
Authors: David Dingli; Kah-Whye Peng; Mary E Harvey; Philip R Greipp; Michael K O'Connor; Roberto Cattaneo; John C Morris; Stephen J Russell Journal: Blood Date: 2003-11-06 Impact factor: 22.113
Authors: Thomas Groot-Wassink; Eric O Aboagye; Matthias Glaser; Nicholas R Lemoine; Georges Vassaux Journal: Hum Gene Ther Date: 2002-09-20 Impact factor: 5.695
Authors: Boris Keil; Graham C Wiggins; Christina Triantafyllou; Lawrence L Wald; Florian M Meise; Laura M Schreiber; Klaus J Klose; Johannes T Heverhagen Journal: Magn Reson Med Date: 2011-03-23 Impact factor: 4.668
Authors: Peng Hou; Dingxie Liu; Meiju Ji; Zhi Liu; James M Engles; Richard L Wahl; Mingzhao Xing Journal: PLoS One Date: 2009-07-10 Impact factor: 3.240
Authors: Ines M Costa; Noor Siksek; Alessia Volpe; Francis Man; Katarzyna M Osytek; Elise Verger; Giuseppe Schettino; Gilbert O Fruhwirth; Samantha Y A Terry Journal: Int J Mol Sci Date: 2021-12-15 Impact factor: 5.923
Authors: Ali M Rad; A S M Iskander; Branislava Janic; Robert A Knight; Ali S Arbab; Hamid Soltanian-Zadeh Journal: BMC Biotechnol Date: 2009-03-27 Impact factor: 2.563